4.79
+0.03(+0.63%)
Currency In USD
| Previous Close | 4.76 |
| Open | 4.81 |
| Day High | 4.82 |
| Day Low | 4.64 |
| 52-Week High | 11.77 |
| 52-Week Low | 1.45 |
| Volume | 232,726 |
| Average Volume | 480,538 |
| Market Cap | 159.01M |
| PE | -1.49 |
| EPS | -3.21 |
| Moving Average 50 Days | 4.44 |
| Moving Average 200 Days | 4.55 |
| Change | 0.03 |
If you invested $1000 in Lexeo Therapeutics, Inc. Common Stock (LXEO) since IPO date, it would be worth $476.62 as of August 31, 2025 at a share price of $4.79. Whereas If you bought $1000 worth of Lexeo Therapeutics, Inc. Common Stock (LXEO) shares 0 years ago, it would be worth $420.18 as of August 31, 2025 at a share price of $4.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Develo
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
GlobeNewswire Inc.
Jun 24, 2025 11:30 AM GMT
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
GlobeNewswire Inc.
May 27, 2025 11:31 AM GMT
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from ne